Company profile GLTO
After 39 days of this quarter the interest is at 126.0. Based on that we can calculate that during remaining 52 days it will total up to 294.0. galecto expected interest is significantly higher compared to previous quarter (+94.7%) and same quarter last year (+182.7%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 48 | 117 143.8% QoQ | 123 5.1% QoQ | 68 -44.7% QoQ |
| 2020 | 52 8.3% YoY -23.5% QoQ | 32 -72.6% YoY -38.5% QoQ | 53 -56.9% YoY 65.6% QoQ | 183 169.1% YoY 245.3% QoQ |
| 2021 | 128 146.2% YoY -30.1% QoQ | 204 537.5% YoY 59.4% QoQ | 222 318.9% YoY 8.8% QoQ | 228 24.6% YoY 2.7% QoQ |
| 2022 | 55 -57.0% YoY -75.9% QoQ | 78 -61.8% YoY 41.8% QoQ | 86 -61.3% YoY 10.3% QoQ | 112 -50.9% YoY 30.2% QoQ |
| 2023 | 104 89.1% YoY -7.1% QoQ | 110 41.0% YoY 5.8% QoQ | 129 50.0% YoY 17.3% QoQ | 151 34.8% YoY 17.1% QoQ |
| 2024 | 126 21.2% YoY -16.6% QoQ | - | - | - |
The average 5 years interest of galecto was 9.23 per week. The last year interest of galecto compared to the last 5 years has changed by 19.83%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 40.89%.
There is not enough data for galectin-3 inhibitor to provide analysis
There is not enough data for galectin-3 inhibitor to provide correlation calculation
There is not enough data for galectin-3 inhibitor to provide analysis
After 39 days of this quarter the interest is at 292.0. Based on that we can calculate that during remaining 52 days it will total up to 681.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 594 | 673 13.3% QoQ | 650 -3.4% QoQ | 813 25.1% QoQ |
| 2020 | 876 47.5% YoY 7.7% QoQ | 638 -5.2% YoY -27.2% QoQ | 543 -16.5% YoY -14.9% QoQ | 646 -20.5% YoY 19.0% QoQ |
| 2021 | 693 -20.9% YoY 7.3% QoQ | 683 7.1% YoY -1.4% QoQ | 628 15.7% YoY -8.1% QoQ | 742 14.9% YoY 18.2% QoQ |
| 2022 | 932 34.5% YoY 25.6% QoQ | 835 22.3% YoY -10.4% QoQ | 673 7.2% YoY -19.4% QoQ | 841 13.3% YoY 25.0% QoQ |
| 2023 | 1028 10.3% YoY 22.2% QoQ | 898 7.5% YoY -12.6% QoQ | 790 17.4% YoY -12.0% QoQ | 928 10.3% YoY 17.5% QoQ |
| 2024 | 292 -71.6% YoY -68.5% QoQ | - | - | - |
The average 5 years interest of fibrosis treatment was 58.99 per week. The last year interest of fibrosis treatment compared to the last 5 years has changed by 14.68%. The interest for fibrosis treatment is seasonal. The last year interest is quite higher compared to 5 years ago. It has increased by 15.72%.
After 34 days of this quarter the interest is at 422.0. Based on that we can calculate that during remaining 58 days it will total up to 1142.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 544 |
| 2019 | 956 75.7% QoQ | 951 -0.5% QoQ | 914 -3.9% QoQ | 975 79.2% YoY 6.7% QoQ |
| 2020 | 990 3.6% YoY 1.5% QoQ | 814 -14.4% YoY -17.8% QoQ | 936 2.4% YoY 15.0% QoQ | 929 -4.7% YoY -0.7% QoQ |
| 2021 | 869 -12.2% YoY -6.5% QoQ | 915 12.4% YoY 5.3% QoQ | 951 1.6% YoY 3.9% QoQ | 917 -1.3% YoY -3.6% QoQ |
| 2022 | 886 2.0% YoY -3.4% QoQ | 897 -2.0% YoY 1.2% QoQ | 859 -9.7% YoY -4.2% QoQ | 860 -6.2% YoY 0.1% QoQ |
| 2023 | 947 6.9% YoY 10.1% QoQ | 946 5.5% YoY -0.1% QoQ | 900 4.8% YoY -4.9% QoQ | 422 -50.9% YoY -53.1% QoQ |
The average 5 years interest of cancer treatment was 70.41 per week. The last year interest of cancer treatment compared to the last 5 years has changed by 0.24%. The interest for cancer treatment is relatively stable in the last 5 years. The last year interest is comparable to 5 years ago. It has changed only by -1.58%.
After 39 days of this quarter the interest is at 426.0. Based on that we can calculate that during remaining 52 days it will total up to 994.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 376 | 633 68.4% QoQ | 668 5.5% QoQ | 625 -6.4% QoQ |
| 2020 | 649 72.6% YoY 3.8% QoQ | 694 9.6% YoY 6.9% QoQ | 712 6.6% YoY 2.6% QoQ | 784 25.4% YoY 10.1% QoQ |
| 2021 | 830 27.9% YoY 5.9% QoQ | 840 21.0% YoY 1.2% QoQ | 853 19.8% YoY 1.5% QoQ | 875 11.6% YoY 2.6% QoQ |
| 2022 | 1065 28.3% YoY 21.7% QoQ | 955 13.7% YoY -10.3% QoQ | 970 13.7% YoY 1.6% QoQ | 981 12.1% YoY 1.1% QoQ |
| 2023 | 1054 -1.0% YoY 7.4% QoQ | 1013 6.1% YoY -3.9% QoQ | 956 -1.4% YoY -5.6% QoQ | 1151 17.3% YoY 20.4% QoQ |
| 2024 | 426 -59.6% YoY -63.0% QoQ | - | - | - |
The average 5 years interest of inflammation treatment was 65.56 per week. The last year interest of inflammation treatment compared to the last 5 years has changed by 21.2%. The interest for inflammation treatment is relatively stable and increasing in the last 5 years. The last year interest is quite higher compared to 5 years ago. It has increased by 61.41%.
There is not enough data for GB2064 to provide analysis
There is not enough data for GB2064 to provide correlation calculation
There is not enough data for GB2064 to provide analysis
There is not enough data for GB0139 to provide analysis
There is not enough data for GB0139 to provide correlation calculation
There is not enough data for GB0139 to provide analysis
There is not enough data for GB1211 to provide analysis
There is not enough data for GB1211 to provide correlation calculation
There is not enough data for GB1211 to provide analysis
After 39 days of this quarter the interest is at 359.0. Based on that we can calculate that during remaining 52 days it will total up to 838.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 335 | 530 58.2% QoQ | 561 5.8% QoQ | 546 -2.7% QoQ |
| 2020 | 529 57.9% YoY -3.1% QoQ | 424 -20.0% YoY -19.8% QoQ | 477 -15.0% YoY 12.5% QoQ | 510 -6.6% YoY 6.9% QoQ |
| 2021 | 490 -7.4% YoY -3.9% QoQ | 493 16.3% YoY 0.6% QoQ | 533 11.7% YoY 8.1% QoQ | 542 6.3% YoY 1.7% QoQ |
| 2022 | 619 26.3% YoY 14.2% QoQ | 549 11.4% YoY -11.3% QoQ | 616 15.6% YoY 12.2% QoQ | 570 5.2% YoY -7.5% QoQ |
| 2023 | 872 40.9% YoY 53.0% QoQ | 947 72.5% YoY 8.6% QoQ | 876 42.2% YoY -7.5% QoQ | 1035 81.6% YoY 18.2% QoQ |
| 2024 | 359 -58.8% YoY -65.3% QoQ | - | - | - |
The average 5 years interest of myelofibrosis was 47.56 per week. The last year interest of myelofibrosis compared to the last 5 years has changed by 51.07%. The interest for myelofibrosis is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 71.48%.
After 39 days of this quarter the interest is at 126.0. Based on that we can calculate that during remaining 52 days it will total up to 294.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 281 | 442 57.3% QoQ | 404 -8.6% QoQ | 381 -5.7% QoQ |
| 2020 | 412 46.6% YoY 8.1% QoQ | 288 -34.8% YoY -30.1% QoQ | 396 -2.0% YoY 37.5% QoQ | 295 -22.6% YoY -25.5% QoQ |
| 2021 | 356 -13.6% YoY 20.7% QoQ | 434 50.7% YoY 21.9% QoQ | 403 1.8% YoY -7.1% QoQ | 363 23.1% YoY -9.9% QoQ |
| 2022 | 360 1.1% YoY -0.8% QoQ | 346 -20.3% YoY -3.9% QoQ | 355 -11.9% YoY 2.6% QoQ | 345 -5.0% YoY -2.8% QoQ |
| 2023 | 405 12.5% YoY 17.4% QoQ | 372 7.5% YoY -8.1% QoQ | 364 2.5% YoY -2.2% QoQ | 338 -2.0% YoY -7.1% QoQ |
| 2024 | 126 -68.9% YoY -62.7% QoQ | - | - | - |
The average 5 years interest of idiopathic pulmonary fibrosis was 28.61 per week. The last year interest of idiopathic pulmonary fibrosis compared to the last 5 years has changed by -4.33%. The interest for idiopathic pulmonary fibrosis is seasonal. The last year interest is comparable to 5 years ago. It has changed only by -14.97%.
There is not enough data for fibrotic lung diseases to provide analysis
There is not enough data for fibrotic lung diseases to provide correlation calculation
There is not enough data for fibrotic lung diseases to provide analysis
There is not enough data for LOXL2 inhibitor to provide analysis
There is not enough data for LOXL2 inhibitor to provide correlation calculation
There is not enough data for LOXL2 inhibitor to provide analysis
There is not enough data for clinical-stage biotechnology company to provide analysis
There is not enough data for clinical-stage biotechnology company to provide correlation calculation
There is not enough data for clinical-stage biotechnology company to provide analysis